Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 5,012

Document Document Title
WO/2023/205802A2
Senescent cells are implicated in aspects of age-related decline in health and contribute to many diseases. Cells can be transformed into a senescent state upon prolonged exposure to the Senescence-Associated Secretory Phenotype (SASP) f...  
WO/2023/205099A2
Here, we describe an infant with congenital dilated cardiomyopathy (cDCM) whose impaired cardiac function and disrupted sarcomere and mitochondria structures were modeled using induced pluripotent stem cells (iPSCs). The causal gene enco...  
WO/2023/205785A2
The present disclosure generally relates to compositions and methods for targeting pro-survival signaling hubs in anoikis-resistant cells, such as anoikis-resistant cancer cells. Embodiments also include methods of changing morphology of...  
WO/2023/201873A1
Disclosed are a BODIPY-based diamond-shaped metal ring, and a method for preparing same, and use thereof in near-infrared emission. According to the present invention, a BODIPY-based 120-degree bipyridine BODIPY ligand molecule 1 having ...  
WO/2023/202092A1
Disclosed in the present invention are a nanoparticle capable of releasing carbon monoxide in a responsive manner, a preparation method therefor and the use thereof. The nanoparticle comprises a shell and an inner core, wherein the shell...  
WO/2023/204581A1
The present invention relates to a three-dimensional hydrogel composite having cancer cell targeting and cancer cell killing effects, and a method for manufacturing same, and more specifically, to: a three-dimensional hydrogel composite ...  
WO/2023/201312A2
The present application provides compounds and methods for treating ocular fibrotic pathologies, including using dopamine D2 receptor antagonists for treating proliferative vitreoretinopathy.  
WO/2023/196405A1
Boronated prodrugs have been developed that are particularly advantageous for use in boron proton capture therapy (BPCT) and boron neutron capture therapy (BNCT). Cancer-targeting moieties, such as heptamethine cyanine dyes (HMCDs), are ...  
WO/2023/196086A2
The present invention relates to combination therapies for treating cancers associated with genetic alterations of the MAPK pathway and/or EGFR In particular, the present invention relates to methods of treating cancer in a subject in ne...  
WO/2023/196218A2
The present invention relates to combination therapies for treating cancers associated with genetic alterations of the MAPK pathway and/or EGFR. In particular, the present invention relates to methods of treating cancer in a subject in n...  
WO/2023/196978A2
Provided herein are methods of identifying a subject with prostate cancer (such as a human or veterinary subject) who will respond to enzalutamide therapy. In particular examples, the methods can determine with high accuracy whether a su...  
WO/2023/196584A2
The application relates to methods for treating chronic pain involving administering to a subject in need thereof a therapeutically effective amount of an inhibitor of endocytosis.  
WO/2023/196821A2
The use of GUCY2C agonists in combination with PDE3 inhibitors in methods of treating the individual who has been identified as experiencing chronic visceral pain or in methods of suppressing appetite are disclosed. Compositions or kits ...  
WO/2023/196891A2
The present invention provides a method for increasing the efficacy of an anticancer therapy by administering to a subject in need thereof at least one compound that at least partially blocks the activity of a bacterial DnaK, and pharmac...  
WO/2023/196820A2
The present disclosure provides, among other things, specific doses of an ENPP1 agent for in vivo treatment of an ENPP1 deficiency, such as for treatment of Generalized Arterial Calcification of Infancy (GACI), Autosomal Recessive Hypoph...  
WO/2023/196952A2
Provided herein is a method for treating a disorder ameliorated by muscarinic receptor activation in a patient in need thereof, comprising administering to the patient a muscarinic orthosteric agonist, such as xanomeline and/or a salt th...  
WO/2023/196576A2
This invention discloses methods of diagnosing and compositions for treating a human subject suspected of having a neurological or hematological disease. Also disclosed are proteins which serve as effective biomarkers for confirming the ...  
WO/2023/193416A1
The present invention relates to the field of biomedicine, and specifically, discloses a near-infrared-responsive injectable microsphere capable of treating a cancer by combining chemotherapy with photothermal therapy and a method for pr...  
WO/2023/194896A1
5-amminolevulinic acid and/or the salts thereof for use in mandibular bone regeneration, in combination with the application of light radiation, wherein the bone regeneration is determined by an increase in the proliferation of osteoblas...  
WO/2023/192955A2
Disclosed herein are compositions and methods for treating cancer. The methods can comprise administrating to a subject with cancer a therapeutically effective amount of an oncolytic virus and a therapeutically-effective amount of a nucl...  
WO/2023/133058A9
Disclosed are methods of treating an ocular disease associated with retinal ischemic injury in a subject comprising administering to the subject a p75NTR modulator, a MSC comprising decreased p75NTR expression or activity or a MSC secrel...  
WO/2023/192938A2
The current disclosure provides for methods for diagnosing, prognosing, and treating cerebral cavernous malformations (CCMs). Also provided are methods for determining the efficacy of therapeutic treatments for CCM, such as those that ma...  
WO/2023/187176A1
The invention concerns an in vitro or ex vivo method for delivering a cargo into a cell, the method comprising: - contacting a cell with one or more photoresponsive organic particles and a cargo, wherein the organic particle is selected ...  
WO/2023/186737A1
Photodynamic light therapy apparatus and methods for treating oral disease are disclosed where one method for reducing or eliminating microbial biofilm or plaque and inflammation in a microbial infected area of the mouth generally compri...  
WO/2023/192815A2
Methods of data analysis, methods of detection, methods of treatment, compositions, and kits associated with treatment of diarrheal disorders are disclosed herein. Inventive concepts disclosed herein can assist stake holders in relieving...  
WO/2023/192988A2
The technology described herein is directed to immune modulatory agents and methods of use. In some aspects, described herein are agents that modulate IL-17a/IL-17 receptor- induced signalling and/or IL-17f/IL-17 receptor-induced signall...  
WO/2023/192220A2
The present disclosure provides methods and systems for diagnosing and treating fibromyalgia in a patient. In one method, an oxygenation level at a muscle location is obtained for the patient; and fibromyalgia is diagnosed in the patient...  
WO/2023/192639A2
In one aspect, methods of treating cancer are provided that comprise: administering to a subject a composition comprising a therapeutically effective amount of: a first agent which inhibits programmed death 1 (PD-1) expression or functio...  
WO/2023/192779A2
The present application relates to the prevention and treatment of respiratory illnesses due to RNA virus infection in patients in need thereof. The application includes compositions of matter, pharmaceutical compositions, combinations, ...  
WO/2023/192880A2
Disclosed herein are methods for treating, ameliorating and/or preventing fibrodysplasia sssificans progressiva (FOP) in a subject in need thereof. The methods include downregulating matrix metalloproteinase 9 (MMP-9) level and/or activi...  
WO/2023/192653A1
The present disclosure provides photocleavable rhodamine probes that facilitate live- and fixed-cell immunofluorescence. The ultra-fast spirocyclization of the dye following cleavage depletes the fluorescence signal, enabling cyclic mult...  
WO/2023/182317A1
The purpose of the present invention is to provide a novel compound which can serve as a component of a boron pharmaceutical agent. The present application provides a boron-containing modified polyrotaxane comprising a plurality of cyclo...  
WO/2023/179866A1
The present invention relates to means for transiently disrupting the neurovascular barrier of a human. More particularly, the invention relates to ultrasound contrast agent for use in treating Amyotrophic Lateral Sclerosis (ALS) in a su...  
WO/2023/178878A1
A microneedle patch for enhancing an accumulation of protoporphyrin IX in a solid tumor and a preparation method therefor. The method comprises the steps of: dissolving albumin in a Dulbecco's culture medium, using the albumin as a templ...  
WO/2023/183776A2
The present disclose provides methods for treating neuroinflammation. Compositions having therapeutic agents targeted to interfering with succinate/succinate receptor signaling are administered to reduce or ameliorate neuroinflammation. ...  
WO/2023/183706A2
The technology relates in part to methods of selecting for and/or treating subjects having cancer, where the subjects are identified as having at least one genetic structural variant that renders them suitable candidates for a treatment ...  
WO/2023/178810A1
The present invention belongs to the technical field of drug-targeting carriers. Disclosed are a co-drug-loaded cell microparticle formulation and a preparation method therefor. The co-drug-loaded cell microparticle formulation comprises...  
WO/2023/183247A2
The present invention provides for methods of treating biogenic amine related conditions. Further provided are methods of detecting biogenic amine related conditions, and selection of treatment for patients in need thereof.  
WO/2023/183936A2
The present invention provides methods, compositions, and combinations for treating cancer via combined use of a compound that forms a covalent bond with a kinase or pseudokinase, or a pharmaceutically acceptable salt thereof, and at lea...  
WO/2023/178964A1
The present invention relates to a method for promoting a drug molecule to reach an action target in a tumor cell, a method for promoting delivery of an endogenous tumor antigen and tumor DNA to a DC, a method for activating a STING path...  
WO/2023/178199A2
The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present disclosure provides bifunctional compounds that can...  
WO/2023/178240A2
Provided herein are novel therapeutic applications of Pyk2 (PTK2B) inhibitors to treat low bone mineral density and/or osteoporosis and to treat, prevent, or delay the progression of neurodegenerative disorders such as Alzheimer's disease.  
WO/2023/176872A1
Provided is a pharmaceutical composition to be used for radiotherapy that comprises a compound represented by formula (I) [wherein: R1 is an aryl group substituted by a substituent selected from an iodine atom, etc., wherein the aryl gro...  
WO/2023/177560A2
The invention provides novel triplet-triplet annihilation upconversion nanoparticles as background free self-standing biological sensors, and devices and methods thereof.  
WO/2023/173824A1
Disclosed in the present invention are a hydrophobic methylene blue fluorescent dye, and a preparation method therefor and the use thereof. The hydrophobic methylene blue fluorescent dye has a structural formula as shown in formula (I), ...  
WO/2023/177841A2
A method is provided for reducing concurrent use of stimulant medications and alcohol. In an example, the method comprises administering to the subject a combination product that includes an effective amount of one or more stimulant medi...  
WO/2023/178179A2
Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Furthe...  
WO/2023/178331A2
An anti-tumor agent is provided to a patient to increase a susceptibility of a tumor within the patient to harmonic excitation. Ultrasonic transducers of a wearable are driven to direct a therapeutic ultrasound signal into tissue of the ...  
WO/2023/173131A2
The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors alone or in combination with immune checkpoint inhibitor therapies for the treatment of breast cancer, including for promoting antitumor immunity and mitigating t...  
WO/2023/173036A2
The present disclosure relates to the use of MASP-2 inhibitors and/or MASP-3 inhibitors and compositions comprising the same for treatment of sickle cell disease, including treatment, reduction, and/or prevention of sickle cell disease s...  

Matches 151 - 200 out of 5,012